Olokizumab is under clinical development by R-Pharm and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Olokizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olokizumab overview

Olokizumab (Artlegia) is a humanized monoclonal antibody. It is formulated as solution for subcutaneous route of administration. Artlegia is indicated for treatment of rheumatoid arthritis and cytokine storm, which is the leading cause of death in coronavirus infection COVID-19. Olokizumab (CDP- 6038) is under development for the treatment of moderate-to-severe rheumatoid arthritis, active juvenile idiopathic arthritis, acute respiratory distress syndrome, interstitial lung disease and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered subcutaneously. The drug candidate is a humanized antibody of the IgG4 isotype that acts by targeting interleukin-6 (IL-6). Olokizumab was also under development for the treatment of Crohn's disease.

R-Pharm overview

R-Pharm (R Pharm) is a pharmaceutical company. It carries out the production of medicines, active pharmaceutical ingredients, laboratory equipment and high-tech medical systems. The company’s pipeline products portfolio includes Nemonoxacin, narlaprevir, Cefilavancin, SCY 078, RPH-120 and Radotinib. R Pharm provides services such as production, commercialization, installation and maintenance of medical systems and staff training. The company offers products in the therapeutic areas of oncology, hematology, immune diseases, antibiotics, antivirals, neurology, cardiology, multiple sclerosis, hemophilia, Covid-19 and diabetes. It also carries out research and development of products and technologies in partnership with Russian and foreign institutes. The company supplies medicinal products and laboratory equipment for the hospitals, federal medical research centers, clinical hospitals, and regional curative and preventive care institutions. It has operations in Russia, the US, Azerbaijan, Uzbekistan, Kyrgyzstan, Kazakhstan, Belarus and Germany. R-Pharm is headquartered in Moscow, Russia.

For a complete picture of Olokizumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.